Comparison of two formulations of botulinum toxin type A for the treatment of glabellar lines: A double-blind, randomized study

Journal of the American Academy of Dermatology

Volumn 55, Issue 6, 2006, Pages 975-980

  Lowe, Philippa ^a   Patnaik, Rickie ^b   Lowe, Nicholas ^a,b  

^a Cranley Clinic   (United Kingdom)

^b Clinical Research Specialists   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BOTULINUM TOXIN A;

ADULT; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG FORMULATION; DRUG TOLERABILITY; ECCHYMOSIS; FACE MUSCLE; FEMALE; HUMAN; MALE; PRIORITY JOURNAL; RANDOMIZATION; SKIN MANIFESTATION; WRINKLE;

ADULT; BOTULINUM TOXIN TYPE A; CHEMISTRY, PHARMACEUTICAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; EUROPEAN CONTINENTAL ANCESTRY GROUP; FACIAL MUSCLES; FEMALE; HUMANS; INJECTIONS, INTRAMUSCULAR; MALE; MIDDLE AGED; NEUROMUSCULAR AGENTS; PATIENT SATISFACTION; RECURRENCE; SKIN AGING; TIME FACTORS; TREATMENT OUTCOME;

EID: 33750808473     PISSN: 01909622     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jaad.2006.07.006     Document Type: Article

References (14)

1. Carruthers J.D., Lowe N.J., Menter M.A., Gibson J., Eadie N., and for the Botox Glabellar Lines II Study Group. Double-blind, placebo-controlled study of the safety and efficacy of botulinum toxin type A for patients with glabellar lines. Plast Reconstr Surg 112 (2003) 1089-1098
2. Carruthers J.A., Lowe N.J., Menter M.A., Gibson J., Nordquist M., Mordaunt J., et al. A multicenter, double-blind, randomized, placebo-controlled study of the efficacy and safety of botulinum toxin type A in the treatment of glabellar lines. J Am Acad Dermatol 46 (2002) 840-849
3. Carruthers A., Carruthers J., Lowe N.J., Menter A., Gibson J., Nordquist M., et al. One-year, randomised, multicenter, two-period study of the safety and efficacy of repeated treatments with botulinum toxin type A in patients with glabellar lines. J Clin Res 7 (2004) 1-20
4. Ascher B., Zakine B., Kestemont P., Baspeyras M., Bougara A., and Santini J. A multicenter, randomized, double-blind, placebo-controlled study of efficacy and safety of 3 doses of botulinum toxin A in the treatment of glabellar lines. J Am Acad Dermatol 51 (2004) 223-233
5. Lowe N.J., Yamauchi P.S., Lask G.P., Patnaik R., and Moore D. Botulinum toxins types A and B for brow furrows: preliminary experiences with type B toxin dosing. J Cosmet Laser Ther 4 (2002) 15-18
6. Smuts JA, de Boulle K, van Coller R, Barnard PWA. An electrophysiological study to demonstrate in vivo differences between two types of botulinum toxin type A (BOTOX® and DYSPORT®). Poster presented at the 8th International Congress of Parkinson's Disease and Movement Disorder, Rome, Italy, June 13-17, 2004.
7. Aoki R., Francis J., Reynolds H., and Leumer D. Comparison of the therapeutic windows of different botulinum neurotoxin preparations in an animal model. Neurology 60 5 Suppl 1 (2003) A212-A213 [P03.088]
8. Aoki K.R. A comparison of the safety margins of botulinum neurotoxin serotypes A, B, and F in mice. Toxicon 39 (2001) 1815-1820
9. Lowe P.L., Patnaik R., and Lowe N.J. A comparison of two botulinum type A toxin preparations for the treatment of glabellar lines: double-blind, randomized, pilot study. Dermatol Surg 31 (2005) 1651-1654
10. BOTOX® Cosmetic (botulinum toxin type A) prescribing information (2004), Allergan, Inc, Irvine (CA)
11. Carruthers J., Fagien S., Matarasso S.L., and the Botox Consensus Group. Consensus recommendations on the use of botulinum toxin type A in facial aesthetics. Plast Reconstr Surg 114 Suppl 6 (2004) 1S-22S
12. Lew H., Yun Y.S., Lee S.Y., and Kim S.J. Effect of botulinum toxin A on facial wrinkle lines in Koreans. Ophthalmologica 216 (2002) 50-54
13. Dressler D., and Hallett M. Immunological aspects of Botox, Dysport and Myobloc/NeuroBloc. Eur J Neurol 13 Suppl 1 (2006) 11-15
14. Ramirez A.L., Reeck J., and Maas C.S. Botulinum toxin type B (MyoBloc) in the management of hyperkinetic facial lines. Otolaryngol Head Neck Surg 126 (2002) 459-467